QuidelOrtho's Respiratory Season Outlook and FCF Conversion Timeline Don't Align in Q2 Call

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $631 million, representing 2% growth on a constant currency basis, excluding China, revenue grew 6%
• EPS: $0.13 adjusted earnings per share for the quarter
• Gross Margin: 44.4%, down 130 basis points year over year

Guidance:

• Revenue for full year 2026 expected in the range of $2.52 billion to $2.6 billion.
• Adjusted EBITDA for full year 2026 expected to be $540 million to $560 million, representing an EBITDA margin range of 21% to 22%.
• Adjusted EPS for full year 2026 expected to be $0.65 to $0.90.
• Free cash flow guidance withdrawn for 2026 due to uncertainty around market dynamics and working capital impacts.

Business Commentary:

Global Revenue and Regional Performance:

• Quidel Ortho reported total revenue of $631 million for Q2 2026, representing 2% growth on a constant currency basis.
• Revenue outside of China grew 6% year-over-year in Q2, with notable growth in North America (6%), JPAC (10%), and Latin America (8%).
• The growth was driven by strong performance across core franchises and regions, particularly in labs and immunohematology.

China Market Challenges:

• Revenue in China declined 23% year-over-year in Q2 2026.
• The downturn was attributed to uncertainty related to proposed IVD pricing guidelines, impacting customer buying behavior and inventory levels.

Respiratory Season Outlook:

• The company's respiratory season forecast has been adjusted due to softer test positivity rates and lower than historical patterns in the US and southern hemisphere.
• Quidel Ortho is assuming a below-average respiratory season for the second half of 2026, impacting their guidance projections.

Revised Full-Year Financial Guidance:

• Quidel Ortho revised its full-year 2026 revenue guidance to $2.52 billion to $2.6 billion, reflecting persistent challenges in China and a cautious approach to respiratory season demand.
• Adjusted EBITDA guidance was also revised to $540 million to $560 million, with adjusted EPS expected to be $0.65 to $0.90.

Focus on Financial Improvement:

• The company aims to improve cash conversion and reduce leverage, with a focus on enhancing working capital efficiency and optimizing returns on instrument investments.
• These efforts are part of a strategic initiative to strengthen the balance sheet and drive sustainable long-term shareholder value.

Sentiment Analysis:

Overall Tone: Neutral

• The call acknowledges strong underlying business performance outside of China and headwinds from China and a softer respiratory season. Management states 'the underlying performance of our business remains strong' but revises full-year guidance lower due to China challenges and a prudent approach to respiratory season assumptions. The tone is focused on disciplined execution and improving cash flow and leverage.

Q&A:

• Question from Jack Meehan (Optron Research): I was wondering if you could talk about what proactive steps you're taking to improve the balance sheet leverage.
  Response: Management's priorities are improving cash conversion, reducing leverage, and increasing returns, focusing on working capital efficiency, optimizing instrument investments, and directing capital to high-return areas.

• Question from Jack Meehan (Optron Research): I was wondering if you had any comment on that [FT article about selling point of care business] and was reporting that Quidel Orto was considered. If you were to consider something like that, just talk through the rationale.
  Response: The company does not comment on market rumors. Their highest priority is maximizing long-term shareholder value, and they regularly evaluate portfolio opportunities but the current focus is on executing strategy and improving financial performance.

• Question from Jack Meehan (Optron Research): If I could squeeze in one more you mentioned that might suggest kind of a lower season. I was wondering if you could elaborate on that. Is it Australia data or something else? Any color would be great.
  Response: The company is taking a more conservative approach to respiratory season forecasting, assuming a market consistent with the lower activity seen in the first half of 2026, based on lower US positivity rates and southern hemisphere data.

• Question from Bill Bonello (Craig Hallam): I'm just curious sort of how you're thinking about the business as a whole, maybe how the strategy, you know, how the board and the management team thinks about risk mitigation. How do you get to a point where you can absorb portions of the business that are underperforming without having it be sort of a major problem for the company as a whole?
  Response: The strength of the core labs and immunohematology business (75% of company) provides stability. The company is taking aggressive mitigation steps, including cost improvement actions, to manage through challenges in China and emerge stronger.

Contradiction Point 1

Rationale for Weaker Respiratory Season Forecast

Contradiction on the basis for revising the respiratory season forecast lower.

Jack Meehan (Opron Research) - Jack Meehan (Opron Research)

2026Q2: The decision is based on lower-than-normal test positivity rates in the US and weaker early-season data from the southern hemisphere, which suggests a later or softer flu season. - Brian Blaser(CEO)

What factors, such as Australia's data, contributed to the respiratory forecast revision suggesting a lower season? - Andrew Brackmann (William Blair)

2026Q1: Revenue growth is expected to accelerate in the second half due to: 1) China impacts being largely in H1, 2) Continued growth in core labs, IH, and Triage, and 3) An average (not declining) respiratory season in H2. - Brian Blaser(CEO), Joseph Busky(CFO)

Contradiction Point 2

Free Cash Flow (FCF) Conversion Target

Timeline for achieving 50%+ FCF conversion is cited as mid-2027 in one quarter, not 2026.

Jack Meehan (Opron Research) - Jack Meehan (Opron Research)

2026Q2: Micah Young highlighted that his priorities are to improve cash conversion, reduce leverage, and increase returns. - Micah Young(CFO)

What proactive steps are you taking to improve balance sheet leverage? - Andrew Cooper (Raymond James)

20260212-2025 Q4: The 50%+ target is... not expected in 2026. It is tethered to margin targets and is anticipated to be a run rate by mid-2027. - Joseph Busky(CFO)

Contradiction Point 3

Strategic Focus and Comment Policy on Potential Business Sale

Contradiction on the company's stance regarding discussing potential strategic options for the point-of-care business.

Jack Meehan (Opron Research) - Jack Meehan (Opron Research)

2026Q2: [Brian Blaser declined to comment on the article, stating the company does not comment on market rumors. He emphasized that the highest priority is maximizing long-term shareholder value, and while the board and management regularly evaluate a broad range of governance and portfolio opportunities, the current focus is on executing the company's strategy...] - Brian Blaser(CEO)

"Can you comment on the [FT article about selling the point-of-care business] and discuss the rationale for considering a sale to Quidel Ortho?" - Patrick Donnelly (Citi)

2026Q1: [The company has no plans to exit China. ... The company has time (until mid-2027) to implement mitigation actions.] - Brian Blaser(CEO)

Contradiction Point 4

Respiratory Season Forecasting Approach

Shift from using historical averages to a more conservative baseline based on recent muted activity.

Jack Meehan (Opron Research) - Jack Meehan (Opron Research)

2026Q2: The company is now assuming a respiratory environment consistent with the muted activity seen in the first half of 2026, rather than using an average historical season as a baseline. - Brian Blaser(CEO)

How does the respiratory forecast revision suggest a lower season? - Andrew Brackmann (William Blair)

20260212-2025 Q4: The increase in depreciation expense... is a more significant factor than the increase in interest expense. - Joseph Busky(CFO) & Brian Blaser(CEO)

Contradiction Point 5

China Business Strategy and Growth Assumption

The 2026 growth assumption shifts from a low single-digit target to acknowledging "aggressive mitigation" for underperformance.

Bill Bonello (Craig Hallam) - Bill Bonello (Craig Hallam)

2026Q2: He emphasized that aggressive mitigation steps are being taken to position the cost structure to manage through the underperformance and emerge stronger. - Brian Blaser(CEO)

How is the company's overall strategic direction shaped by the board and management team's approach to risk mitigation? - Tycho Peterson (Jefferies)

20260212-2025 Q4: The 2026 guide assumes low single-digit growth in China, consistent with 2025. - Joseph Busky(CFO)